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Objective: Nitric oxide (NO) has been implicated in the local regulation of bone metabolism. However, the
contribution made by speciﬁc nitric oxide synthase (NOS) enzymes to skeletal development is unclear.
The objective of this study was to examine the effects of inactivation of neuronal nitric oxide synthase
(nNOS) on cartilage development in mice.
Design: Mice carrying a null mutation in the nNOS gene were used to address our objectives. Histological
staining, immunohistochemistry and in situ analyses were employed along with real-time reverse
transcriptase - polymerase chain reaction (RT-PCR).
Results: nNOS-null mice show transient growth retardation and shorter long bones. nNOS-deﬁcient
growth plates show a reduction in replicating cells. Reduced chondrocyte numbers may in part be due
to slower cell cycle progression and premature cell cycle exit caused by decreased cyclin D1 and
increased p57 expression in mutants. In addition, apoptosis was increased as shown by increased
cleaved-caspase 3 staining in hypertrophic chondrocytes in mutants. Real-time PCR demonstrated that
expression of early chondrocyte markers such as Sox genes was reduced in mutant mice, while
expression of prehypertrophic markers such as RORa was increased. Histological sections also demon-
strated thinner cortical bone, fewer trabeculae and reduced mineralization in mutant mice.
Conclusions: These data identify an important role of nNOS in chondrocyte proliferation and endo-
chondral bone growth and demonstrate that nNOS coordinates cell cycle exit and chondrocyte differ-
entiation in cartilage development.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
NO is a small signaling molecule with important regulatory
effects in many tissues. It can function as an intracellular
messenger, an autacoid, a paracrine substance, or a neurotrans-
mitter1. The versatile functions of NO stem from the chemical
properties of the compound. NO is a gaseous uncharged free radical
with an unshared electron that can react with many molecules and
proteins to regulate biological processes2. Because it is uncharged,
it can freely diffuse to the surrounding cells, making it ideal as
a signaling molecule3. In most processes, NO activates soluble
guanylyl cyclase (GC), resulting in increased levels of the intracel-
lular secondary messenger cyclic guanosine monophosphateto: F. Beier, Department of
dicine and Dentistry, Univer-
1. Tel: 519-661-2111x85344;
s Research Society International. P(cGMP)1,2, but other modes of signaling such as protein nitro-
sylation also contribute to the biological effects of NO2,4. Different
cells and tissues have different abilities to produce NO. In general,
low levels of NO are produced from constitutive NOSs, (endothelial
NOS/eNOS and neuronal NOS/nNOS) and high levels of NO stem
from inducible nitric oxide synthase (iNOS). The ultimately effects
of NO are determined by its concentration, its source, and the
availability of molecules in the microenvironment that it can react
with. Over years NO has been known to regulate bone cell
metabolism, bone remodeling and chondrocyte physiology in
osteoarthritis (OA)3,5,6, but the contributions made by speciﬁc NOS
enzymes to bone growth and development are unclear7,8. In light of
the prevalent connections between chondrocyte differentiation
and the pathogenesis of OA9, and the well-known roles of NO in OA,
the elucidation of the roles of individual NOS genes in cartilage
development is of great importance.
Formation of the skeleton is achieved through two independent
mechanisms: intramembranous and endochondral ossiﬁcation10.
Endochondral bone formation is a precisely regulated process andublished by Elsevier Ltd. All rights reserved.
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involves the steps of chondrogenesis, chondrocyte proliferation,
differentiation, and hypertrophy and eventually replacement of
cartilage tissue by bone tissue and bone marrow3,10e13. During
postnatal development, proliferation and hypertrophy occur in
a controlled fashion in the cartilage growth plate that determines
the ﬁnal length of the adult bone. Within the growth plate, chon-
drocytes are organized in distinguished zones (resting, prolifer-
ating, prehypertrophic and hypertrophic zones) based on their
morphologic shapes and gene expression patterns11. If any steps
during this process are not properly regulated, skeletal diseases will
result, such as different types of chondrodysplasias14. In addition,
links between skeletal developmental and the pathogenesis of OA
are becoming evident. For example, both disturbances of normal
endochondral ossiﬁcation and ectopic initiation of chondrocyte
hypertrophy in articular cartilage have been implicated in OA15,16.
Thus, investigations into the mechanisms controlling normal
cartilage development are essential for our understanding of OA
pathogenesis.
We recently described cartilage development in eNOS- and in
iNOS-deﬁcient mice that both display reduced bone growth17,18.
This effect appears to be due to a chondrocyte-autonomous role of
eNOS in chondrocyte proliferation. However, nNOS mRNA levels
were upregulated in eNOS-null chondrocytes, suggesting that nNOS
partially compensates for the loss of eNOS. nNOS knockout (KO)
mice have been found to be viable, have enlarged stomachs due to
pyloric muscle hypertrophy, exhibit insulin resistance and resis-
tance to neural damage as the result of stroke induced by middle
cerebral artery ligation19. nNOS expression has been detected
during skeletal development and fracture healing, and previous
studies showed reduced bone remodeling with a signiﬁcant
reduction in osteoblast and osteoclast numbers in nNOS-deﬁcient
mice19. However, the exact mechanisms and functions of nNOS in
earlier stages of skeletal development have not been described. In
this study, we investigated the effects of nNOS deﬁciency on
cartilage development and endochondral bone formation.
Materials and methods
Antibodies and reagents
All reagent materials and general chemicals were obtained from
Invitrogen, Sigma or VWR unless otherwise stated. The following
antibodies were employed in this study: Kip2/p57 #sc8298 (rabbit
antibody against human protein), RORa #sc28612 (rabbit antibody
against human protein), activating transcription factor 3 (ATF3)
#sc188 (rabbit antibody against human protein), Sox9 #sc-17340
(goat antibody against human protein), c-Fos #sc-52 (rabbit anti-
body against human protein), Goat-anti-mouse #sc2005, Goat-
anti-rabbit #sc2004 (all from Santa Cruz Biotechnology); Cyclin
D1 (SP4) #9104-S1 (rabbit antibody against human, mouse and rat
proteins; NeoMarkers Inc.); proliferating cell nuclear antigen
(PCNA) #2586 (mouse antibody against human, mouse and rat
proteins; Cell Signaling Inc.).
Mouse breeding and genotyping
Micewith a deletion of the nNOS gene (Stock #2986) and control
mice in the C57/BL6 background were obtained from Jackson
Laboratory (Bar Harbor, ME), and exposed to a 12-h light-dark cycle
and fed tap water and regular chow at libitum19. All procedures
involving animals were approved by the University of Western
Ontario Animal Care and Use Committee. For PCR genotyping, tail
snips were used to prepare DNA for PCR analysis. PCR genotyping
was performed by simultaneous ampliﬁcation of the wild type andnull nNOS alleles as described9,19. PCR fragments were analyzed by
agarose gel electrophoresis.
Histology and immunohistochemistry
After dissection of mice, bones were rinsed in PBS, ﬁxed in 4%
paraformaldehyde (PFA) overnight, placed in 10% formalin solution
and sent for embedding and sectioning into 4 mm sections at the
Molecular Pathology Core Facility at the Robarts Research Institute
(London, Ontario, Canada). Following sectioning, boneswere stained
with hematoxylin and eosin or safranin O/fast green using standard
protocols20,21 orused for immunohistochemistryasdescribedbelow.
For immunohistochemistry, sections unstained prior to usewere
dewaxed and incubated in 3%H2O2 for 15 min at room temperature,
followed by boiling for 20 min in 10 mM sodium citrate (pH 6.0)
and blocking with 5% goat serum at room temperature for 30 min,
as described17,21e23. Sections were incubated with primary anti-
body overnight at 4C and secondary antibodies according to the
manufacturers’ recommendations. After washing, sections were
incubated for 1e10 min with DAB (3,30-diaminobenzidine tetrahy-
drachloride) substrate solution (Dako North America, Inc.), washed
and mounted. All images were taken at room temperature with
a Retiga EX camera connected to a Leica DMRA2 microscope using
OpenLab 4.0.4 software. For cell counts in sections, all cells and cells
positive for staining with primary antibody were counted from
three different areas of one section. Sections from at least three
mice per genotype, and at least three sections from every mouse,
were analyzed, and averages and standard deviation from all
counts/genotype are shown.
RNA isolation and real-time RT-PCR
Total RNA was isolated from epiphyseal cartilage of long bone
from newborn mice using TRIzol (Invitrogen), according to the
manufacturer’s recommendations. TaqMan real-time PCR was
performed as described21,24 with primers and probe sets from
Applied Biosystems (Sox5 Mm00488381_m1; Sox6 Mm00488
393_m1; Sox9 Mm00448840_m1; P57 Mm00438170_m1; MMP13
Mm00439495_m1; Igf1 Mm00439560_m1; Gapdh Mm99999
915_g1). Data were normalized to Gapdh mRNA levels and repre-
sent averages and SEM from direct comparison of mutant and
control littermates from three different crosses.
Statistical analysis
All experiments were performed with at least three indepen-
dent litters (each litter representing one independent experiment).
Statistical signiﬁcance of experiments was determined by a one-
way analyses of variance (ANOVA) with Bonferroni post test using
GraphPad Prismversion 4.00 forWindows, GraphPad Software, San
Diego, California, USA. Data presented in the graph showmean and
95% conﬁdence intervals.
Results
Inactivation of nNOS gene results in reduced bone length
We used nNOS-deﬁcient mice to address the role of this gene in
cartilage development in vivo. KO mice were viable and fertile, and
the general appearance of stature and gait was unremarkable, but
male KO mice appeared more aggressive. Body weight and length
were not signiﬁcantly changed in nNOS/ mice at birth. Growth
retardation developed in surviving nNOS/ mice in the postnatal
period at day 21e42, as shown by reduced body weight and length
[Fig. 1(A)]. Body weight showed signiﬁcant reduction at postnatal
Fig. 1. Loss of nNOS results in reduced growth and bone length. Analyses of body weight and length of wild type and nNOS homozygote null mice showed that growth retardation
developed in nNOS-null mice during the ﬁrst 42 days of their life (A). Measurement of selected individual bones conﬁrmed reduced bone length in tibiae in postnatal day 21 mutant
mice (B). At least eight mice per genotype are shown for each data point. (*P< 0.05, mean 95% conﬁdence interval) (WT: wild type; KO: knockout).
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analyses at 3-month and 1 year of age demonstrated similar body
weight and body length between genotypes (data not shown),
suggesting that KO mice catch up during aging. Observation of
alcian blue/alizarin red-stained skeletons showed no obvious
morphological changes in the axial and appendicular skeleton of
mutants (data not shown), but measurement of selected individual
bones conﬁrmed reduced bone length in tibiae in mutant mice at
postnatal day 21 [Fig. 1(B)].
nNOS deﬁciency results in reduced chondrocyte proliferation in the
growth plate
To elucidate the cellular basis for reduced bone growth, we
analyzed growth plate organization at different developmental
stages. Growth plates from newborn mutant mice displayed
a similar chondrocyte arrangement in resting, proliferative and
hypertrophic zones as control mice [Fig. 2(A)]. Measurement of the
lengths of resting, proliferating and hypertrophic zones did not
show signiﬁcant differences (data not shown) between genotypes,
and cells in the resting and hypertrophic zones of nNOS-null mice
did not appear markedly different from controls. However, nNOS/
growth plates appeared slightly disorganized with fewer and
shorter columns, especially in the proliferative zone in the center of
the growth plates. Some cells also appeared to be smaller in size
[Fig. 2(A,B)].
Since our mutant mice showed lower cell numbers in the
proliferative zone of the growth plate, we next examined chon-
drocyte proliferation and apoptosis. Immunohistochemical staining
for PCNA demonstrated a reduction in positive cells in mutant mice
[Fig. 3(A)] which was conﬁrmed by cell counts [Fig. 3(B)]. Reduced
cell numbers could also be due to increased cell apoptosis, which
we examined by immunohistochemical staining for cleaved(activated) caspase 3. Staining for cleaved caspase 3 was increased
in hypertrophic chondrocytes of mutant mice [Fig. 3(C)].
To elucidate the reason for reduced proliferation in nNOS/
mice, we examined cell cycle protein expression in growth plates.
Immunohistochemical staining for cyclin D1, which controls
progression through the G1 phase of the cell cycle11, demonstrated
a reduced number of positive cells in mutant mice [Fig. 3(D)]. The
transcription factor ATF3 acts as a repressor of cyclin D1 tran-
scription in chondrocytes25. Immunohistochemistry demonstrated
earlier induction of ATF3 expression in late proliferating chon-
drocytes and overall stronger ATF3 staining in nNOS-deﬁcient
growth plates [Fig. 3(E)], suggesting that premature induction of
ATF3 expression in mutant mice leads to repression of cyclin D1
transcription and chondrocyte proliferation.
Increased differentiation in nNOS-deﬁcient chondrocytes
Since reduced chondrocyte proliferation is often associated with
premature cell cycle exit and maturation11, we examined the expres-
sion of additional markers of prehypertrophic chondrocytes. Expres-
sion of the cell-cycle inhibitor p57, which promotes cell cycle exit and
is required for normal chondrocyte differentiation,was found strongly
increased by immunohistochemistry in mutant mice [Fig. 4(A)].
Immunohistochemistry also showed a similar increase in the number
of cells expressing the transcription factors c-Fos [Fig. 4(B)] and RORa
[Fig. 4(C)], both of which have been implicated in prehypertrophic/
hypertrophic chondrocyte-speciﬁc gene expression26,35.
nNOS deﬁciency affects cartilage-speciﬁc gene expression
In parallel, we analyzed expression of several cartilage marker
genes in the mutant mice by real-time reverse transcriptase -
polymerase chain reaction (RT-PCR), using RNA directly extracted
Fig. 2. Lack of nNOS causes reduced numbers of proliferating chondrocytes. Safranin O/Fast Green staining of tibia growth plate sections from newborn mice demonstrated similar
growth plate architecture in both genotypes (A and B). Detailed analyses of H&E stained sections in the resting, proliferative, and hypertrophic zones showed that the major
differences occur in the proliferative zone (B). (RC: resting cells; PC: proliferating cells; HC: Hypertrophic cells). (Scale bar ¼ 200 mm).
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sion for Sox5 and Sox6 that are important for many stages of
chondrocyte differentiation [Fig. 5(A,B)]. Real-time RT-PCR also
demonstrated increased expression of prehypertrophic and
hypertrophic markers p57 and Mmp13 [Fig. 5(C,D)]. Transcript
levels for Igf1, which plays an important role in regulating skeletal
development and bone remodeling21, were also strongly decreased
in the mutant mice [Fig. 5(E)]. Interestingly, we also demonstrated
upregulated eNOS and iNOS mRNA levels in the nNOS KO cartilage
samples [Fig. 5(F,G)].
Loss of nNOS results in reduced trabecular bone and calcium
deposition
To analyze whether nNOS deﬁciency had effects on later stages
of endochondral ossiﬁcation, we next examined trabecular bone
formation and ossiﬁcation patterns in mutant mice. Von Kossa
staining demonstrated mineralization of trabecular and cortical
bone in tibia sections from neonate and postnatal day 21 mice,
which was clearly decreased in mutant mice [Fig. 6(A)]. A lack of
trabecular structures was also seen by picrosirius red staining for
ﬁbrillar collagen [Fig. 6(B)], suggesting that these effects are not
simply due to delayed mineralization, but to a delay or reduction in
bone formation. Secondary ossiﬁcation centers were advanced in
control mice at postnatal day 12, but less advanced in age-matched
KO mice, demonstrating that nNOS deﬁciency results in delayed
secondary ossiﬁcation [Fig. 6(C)].Discussion
The signaling pathways that control growth plate chondrocyte
proliferation and differentiation during endochondral ossiﬁcation
are incompletely understood. In this study, we provide evidence for
an important role of the nNOS gene in these processes. Our data
show that genetic ablation of nNOS results in reduced chondrocyte
proliferation and endochondral bone growth in vivo. Analyses of
these changes in cellular and molecular levels suggest that these
effects are likely due to altered expression of several cell-cycle
proteins, such as cyclin D 1 and p57, as well as modulation of
other genes with known roles in cartilage differentiation, including
Sox genes, RORa and c-Fos.
Although there were no obvious morphological changes in the
axial and appendicular skeleton, measurement of individual bone
conﬁrmed shorter tibiae and femurs in postnatal day 21 mutant
mice. Detailed analyses of nNOS null tissue sections revealed
several abnormalities, most notably reduced chondrocyte prolif-
eration. nNOS-deﬁcient growth plates resemble those we observed
in mice lacking the eNOS or iNOS genes17,18 and also share simi-
larities to those in mice deﬁcient for C-type natriuretic peptide
(CNP)27. Because both NO and CNP stimulate the production of
cGMP via soluble or particulate GCs27, these similarities are not
surprising and further document the importance of cGMP signaling
in endochondral bone formation. However, it should be noted that
a major phenotype of CNP null mice is a reduction in the length of
the hypertrophic zone27 that we did not observe here. One
Fig. 4. Increased expression of early hypertrophic markers in nNOS-deﬁcient chondrocytes. Expression of the cell-cycle inhibitor p57, which promotes cell cycle exit and is required
for normal chondrocyte differentiation, was found increased in mutant mice by immunohistochemical analyses of newborn tibia sections (A). Immunohistochemistry also showed
a similar increase in the number of cells expressing the transcription factors c-fos (B) and RORa (C) in sections from newborn mutants (Scale bar¼ 200 mm). Representative pictures
from at least three independent experiments are shown.
Fig. 3. nNOS deﬁciency reduces chondrocyte proliferation and increases apoptosis. Immunohistochemical staining of newborn tibia sections for proliferating cell nuclear antigen
(PCNA; A) showed a reduction in stained cells in mutant mice, which was conﬁrmed by cell counts (B); at least six mice per genotype are shown (*P< 0.05; mean 95% conﬁdence
interval). Increased staining for cleaved caspase 3 was found in hypertrophic chondrocyte in mutant tibia sections (C). In addition, immunohistochemistry showed that less cells
expressed cyclin D1 (D) while expression of ATF3 protein was increased (E) in growth plates from newborn mutant mice (C) (Scale bar¼ 200 mm). Representative pictures from at
least three independent experiments are shown.
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Fig. 5. nNOS deﬁciency affects cartilage-speciﬁc gene expression. Real-time RT-PCR revealed decreased expression for Sox5 and Sox6 transcripts (A, B) and increased expression of
mRNA levels for p57 andMmp13 (C, D) in cartilage of KO mice. Transcript levels for Igf1were signiﬁcantly decreased in the mutant mice (E). mRNA levels of iNOS and eNOSwere also
found upregulated in nNOS KO cartilage (F, G). At least four independent experiments per genotype are shown (*P< 0.05; mean 95% conﬁdence interval).
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when all three NOS genes are expressed highly7, eNOS and/or iNOS
(or potentially CNP) can compensate for the loss of nNOS, while
they may not be able to do so in the proliferating zone.
The growth plate phenotype of nNOS KO mice is similar to that
of eNOS and iNOS null mice17,18. Given the similar functions the
three NOS proteins and their similar expression in the growth
plate7, the similarities between the phenotypes of the three KO
lines were to be expected. In eNOS KO mice we only observed the
upregulation of the nNOS gene, while eNOS and iNOS genes are both
upregulated in nNOS KO mice. The compensatory regulation of
transcripts of NOS enzymes may explain the relatively minor
phenotype we observed in nNOS KO mice and provide further
evidence for overlapping functions among NOS genes. It is likely
that simultaneous inactivation of NOS genes would have more
severe outcomes. However, it should be noted that mice lacking all
three NOS genes have been described28. Although those mice show
a very high rate of lethality (85%), the surviving triple NOS KO mice
live a surprisingly normal life29, suggesting that additional
compensatory mechanisms may exist.
nNOS inactivation results in reduced chondrocyte proliferation
and increased apoptosis. However, increased staining for active
caspase 3 was restricted to terminally differentiated hypertrophic
chondrocytes, suggesting that apoptosis plays no or only a minor
role in the reduced numbers of proliferating chondrocytes. Instead,
one of the major reasons for the reduced proliferation appears to be
the induction of the transcription factor ATF3, which is able tosuppress cyclin D1 transcription25. Cyclin D1 expression is induced
by many mitogenic stimuli and pathways in chondrocytes11. Our
studies suggest that in addition to positive regulation through
transcription factors such as ATF2 and CREB30e33, cyclin D1 tran-
scription is also under negative regulation by ATF325. The cyclin-
dependent kinase inhibitor p57 is a second cell cycle protein
showing altered expression in the absence of eNOS, iNOS or nNOS.
Immunohistochemistry showed earlier and broader expression in
mutant mice, along with other prehypertrophic markers such as
RORa. At the moment, it is unknown whether NO signaling regu-
lates cyclin D1 and p57 expression through a common pathway or
through different effectors. It is also possible that premature
differentiation to prehypertrophic chondrocytes is due to the
reduced expression of Sox5 and Sox6 in nNOS KO cartilage, but the
relationship between these transcription factors and cyclin D1
expression has not been addressed. Finally, reduced expression of
Igf1 could also contribute to the phenotype of nNOS KO mice,
although the reduced growth in Igf1-deﬁcient mice is largely due to
smaller size of hypertrophic chondrocytes, as opposed to the
primary effect on cell proliferation in our mice34.
Loss of nNOS results in reduced von Kossa staining of cortical
and trabecular bone. Picrosirius red staining suggests that this
effect is due to paucity of trabecular structures per se, not just
a delay in mineralization. At the moment, it is unclear whether this
phenotype is secondary to defects in cartilage development or due
to intrinsic functions of nNOS in osteoblasts or osteoclasts. Cell
type-speciﬁc KO models will be required to resolve this question.
Fig. 6. nNOS deﬁciency leads to reduced trabecular bone and calcium deposition. Mineralization of trabecular and cortical bone shown by Von Kossa staining in tibia sections from
postnatal day 21 mice was clearly decreased in mutant mice (A). A similar lack of trabecular structures was also seen by picrosirius red staining for ﬁbrillar collagen (B). Secondary
ossiﬁcation centers were advanced in control mice at postnatal day 12, but delayed in mutant mice (C). (Scale bar: 200 mm for A, B, D; 50 mm for C) Representative pictures from at
least three independent experiments are shown.
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drocyte proliferation apoptosis and maturation. Loss of nNOS
affects numerous aspects of cartilage physiology, including chon-
drocyte proliferation and gene expression, as well as mineralization
of bone. Reduced chondrocyte proliferation may in part be due to
premature cell cycle exit shown by decreased cyclin D1 and
increased p57 expression in mutants. It appears likely that the
overall phenotype of nNOS-deﬁcient mice is a combination of
alternations in all these aspects. Further investigations into the
speciﬁc mechanisms involved will result in a better understanding
of physiological and pathological skeletal development and asso-
ciated diseases, such as OA and osteoporosis.
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